CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 42 enrolled
Drug / intervention
MT-6548drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03402386
NCT03402386Phase 3Completed
CompareCT.gov

A Phase III, Open-label Study of MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Tanabe Pharma Corporation·interventional·Posted Jan 18, 2018·Updated Apr 6, 2026

In Brief

A Phase 3 clinical trial evaluating MT-6548 for Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease. Completed, enrolled 42 participants across 17 sites.

Detailed Summary

To evaluate the efficacy and safety of MT-6548 in peritoneal dialysis subjects with anemia associated with chronic kidney disease

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia; Peritoneal Dialysis Dependent Chronic Kidney Disease
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJan 18, 2018
Enrollment StartJan 3, 2018
Primary CompletionNov 22, 2018
Study CompletionDec 20, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.5 years ago

Interventions

MT-6548drug

Oral tablet